← back

Untitled

A lab that cannot prove who touched a result has a data problem before it has a security problem. EMA guidance for computerized systems in clinical trials requires secure, computer generated, timestamped audit trails for electronic data, and NIAID clinical research guidance is just as direct about attributable data, protected trail entries, and exportable records that can survive scrutiny across sites and participants. That sounds procedural until the morning a study coordinator is locked out of the CTMS, or a site nurse cannot verify a patient visit because the identity layer is wobbling and the access policy was built for the happy path. Then the argument stops being philosophical.

Zero trust helps here because it treats location as a weak signal and identity as the control point. NIST’s zero trust architecture says communication is secured regardless of network location and that location alone does not imply trust. In pharma terms, that means the instrument network, the trial platform, the quality system, and the manufacturing execution layer should each decide access from the user, device, and session context, not from a vague assumption that anything inside the VLAN is civilized. The irony is familiar to anyone who has watched a “segmented” environment fail at 2am. The diagram looked tidy. The blast radius did not.

Third party risk is where the polished story starts sweating. Life sciences vendors now run everything from randomization to pharmacovigilance workflows to cloud hosting, and current industry material keeps circling back to continuous oversight, documented qualification, and real time monitoring rather than annual reassurance theater. That matters because a partner’s weak identity controls or stale privileged access can halt release testing, freeze a clinical data pipeline, or force a site offline while everyone searches for a paper trail that should have been generated automatically. If the boundary with a CRO, CDMO, lab service, or SaaS platform is porous, then the partner inherits your outage and your compliance problem together.

The practical shape of the answer is boring in the best way. Identity management, least privilege, MFA, session logging, device posture checks, and tightly defined network and application boundaries are what keep the system standing when a certificate expires, a contractor leaves, or a vendor gets noisy. Those controls also produce evidence, which is the part executives underprice until an auditor asks for a decision record and the room goes silent. Audit traceability is the memory of the operation.

A manufacturing site feels this first. If a MES or historian account is overbroad, if the LIMS API trusts every machine that can reach it, if a remote maintenance connection stays open because no one wants to break the line, then continuity becomes a wish instead of an engineering property. A security boundary that is too soft lets production keep moving until the wrong change, the wrong session, or the wrong vendor account turns a controlled process into a stoppage with paperwork. Good security in this world is a continuity feature with legal consequences.

You can modernize the stack, rename the vendors, and buy a prettier dashboard, but if the identity model is vague and the rollback story is decorative, you have only relocated the outage. If this is the part that made someone in validation wince, hello@example.com is a calmer place to start the conversation.' tags: - technology-trends - cybersecurity - zero-trust title: Cybersecurity is the lab bench now type: technology_trends

Related

Roche’s Divarasib Bispecific Sets a New KRAS G12C Bar in Lung CancerThe Factory Is Connected. The Evidence Is Still Missing.The Semantic Layer Is the Infrastructure